NIPPV Linked to Increased Hospital Mortality Rates in Small Group of Patients

Released: 10/18/2011 2:05 PM EDT
Embargo expired: 10/21/2011 12:05 AM EDT
Source Newsroom: American Thoracic Society (ATS)
Contact Information

Available for logged-in reporters only

Citations AJRCCM

Newswise — Although increased use of noninvasive positive-pressure ventilation (NIPPV) nationwide has helped decrease mortality rates among patients hospitalized with chronic obstructive pulmonary disease (COPD), a small group of patients requiring subsequent treatment with invasive mechanical ventilation (IMV) have a significantly higher risk of death than those placed directly on IMV, according to researchers in the United States who studied patterns of NIPPV use.

The findings were published online ahead of the print edition of the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.
Patients hospitalized with COPD frequently require mechanical ventilation – either invasive or noninvasive – to help them breathe. IMV requires insertion of a rigid tube into the airway which allows oxygen to enter and exit the lungs freely. Invasive methods often involve a significant risk of infection which can occur when bacteria gather around the tube and its fittings. As a result, NIPPV methods are used when possible to minimize infection risks. NIPPV relies on the use of a mask to deliver pressurized air through the mouth and nose. The two common forms of NIPPV are continuous positive airway pressure (CPAP), which provides a continuous pressurized stream of air, and bilevel positive airway pressure (BPAP), which offers different pressures for inhalation and exhalation.

“We performed the first examination of the patterns and outcomes of NIPPV treatment for acute exacerbations of COPD in clinical practice nationwide, using data from an estimated 7,511,267 million hospital admissions in the United States during 1998-2008,” said Fernando Holguin, MD, MPH, an assistant professor of medicine in the Pulmonary, Allergy and Critical Care Division at the University of Pittsburgh School of Medicine. “The current study, to the best of our knowledge, is the first to report a dramatic shift towards NIPPV use for treating respiratory failure from acute exacerbations in the United States.”
The increase is consistent with results reported by investigators in smaller studies, he said.

For this study, researchers from the University of Pittsburgh, Emory University, the University of Illinois at Chicago and the University of Kentucky reviewed clinical patient data gathered by the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) database between 1998 and 2008. The researchers examined changes in the frequency of NIPPV and IMV use from 1998 to 2008, and compared patient demographics, income status, payer type, hospital region and hospital type among patients who initially received NIPPV, IMV or no respiratory support after hospital admission. They also examined in-hospital mortality, length-of-stay and total hospitalization charges, and compared those outcomes among patient groups.

At the completion of the study, they found that although the annual number of hospitalizations for acute exacerbations remained relatively constant during the 10-year period, there was a progressive increase in the use of NIPPV and a progressive decrease in use of IMV; during the entire study period, there was a fourfold increase in the use of NIPPV, which had grown to overtake IMV as the most frequently used form of respiratory support for patients hospitalized with acute exacerbations in the United States.

They also found that despite a steady decline in mortality among most patients studied, patients who used NIPPV and were then transitioned to IMV had significantly higher mortality rates than other patients, and that the mortality rate in these transitioned patients increased during the study period while mortality rates of other groups declined. Patients in this group also experienced the greatest increase in hospital charges and longest hospital length-of-stay.

“The concerning finding in our analysis was the high mortality in the group of patients who, despite initial treatment with NIPPV, required subsequent placement on IMV,” said Dr. Holguin, who also serves as the assistant director of the University of Pittsburgh Medical Center's Asthma Institute at the University of Pittsburgh School of Medicine. “It is notable that this finding is contrary to that found in the carefully monitored patient environment of clinical trials, where those transitioned from NIPPV to IMV did not have higher mortality than patients placed on IMV from the beginning.”

Dr. Holguin added that the overall trend toward greater use of NIPPV was likely due to several factors, including clinical trials linking NIPPV with a decrease in hospital mortality, increased confidence in using NIPPV and the ability to use NIPPV outside of the intensive care unit.
“These results suggest that healthcare providers should continue to be aggressive with the use of noninvasive ventilation for patients with acute exacerbations, but definitely should intensively monitor sick patients, intervene early in the absence of improvement, and carefully examine if transitioning to IMV is in the interest of a patient with a poor prognosis,” he said.

Contact for article: Fernando Holguin, MD, MPH, UPMC Montefiore Hospital - NW628, 3459 Fifth Avenue, Pittsburgh, PA 15213.
Phone: 412-692-2817
Email: holguinf@upmc.edu

Link to original article: http://www.thoracic.org/media/press-releases/resources/1094OCR3.pdf

About the American Journal of Respiratory Research and Critical Care Medicine:
With an impact factor of 10.191, the AJRRCM is a peer-reviewed journal published by the American Thoracic Society. It aims to publish the most innovative science and the highest quality reviews, practice guidelines, and statements in the pulmonary, critical care, and sleep-related fields.

Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society’s 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy.


Comment/Share